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Summary DNA ploidy and S-phase fraction (SPF), determined by flow cytometry were studied in 118
patients with muscle-invasive transitional cell carcinoma (TCC) of the urinary bladder, scheduled for cystec-
tomy after pre-operative radiotherapy (20 Gy/l week) with or without systemic cisplatin-based neo-adjuvant
chemotherapy. The correlation between these parameters and immunohistochemically demonstrated p53,
c-erbB-2 and HCG was also investigated. There were 16 DNA diploid and 102 DNA non-diploid tumours.
DNA ploidy was not related to the T (all 118 patients) or pN (58 patients) category, occurrence of stage
reduction or cancer-related 5 years survival. Patients with high SPF tumours tended, however, to have a better
prognosis than those with low SPF TCC reaching the level of significance (P<0.05) for those patients who
had high SPF tumours and received neo-adjuvant chemotherapy. Fifty-one of the tumours were p53 positive.
p53 positive tumours were significantly more often found in TCC with low SPFs than in those with high SPFs.
Respectively 12 and 9% of the tumours were HCG and c-erbB-2 positive, without correlation to DNA ploidy
or SPF. We conclude that DNA ploidy does not represent a prognostic parameter in muscle-invasive operable
bladder carcinomas. A high SPF, determined by FCM, may be helpful to identify patients with chemotherapy-
sensitive TCC of the urinary bladder.
The prognostic role of flow cytometrically (FCM) determined
DNA content in superficial bladder cancer has been shown in
several reports: DNA aneuploidy or the existence of multiple
DNA stemlines were correlated with a high frequency of
tumour recurrence, progression and poor survival (Gustafson
et al., 1986; Tribukait, 1987; Lipponen et al., 1991; Masters
et al., 1989; Norming et al., 1992). In muscle-invasive bladder
cancer the significance of DNA ploidy is less obvious (Lip-
ponen et al., 1991; Jenkins et al., 1990; Jacobsen et al., 1989;
1991; Badalament et al., 1990; Wijkstrom et al., 1992; Hug et
al., 1992). Even less is known about the clinical significance
of the S-phase fraction (SPF) in muscle-invasive bladder
cancer as determined by DNA FCM, though some correla-
tion has been suggested between this parameter and metas-
tatic regional lymph node involvement (Lipponen 1991;
Shaaban et al., 1990) or survival (Lipponen et al., 1991;
Jacobsen et al., 1992).
The present study attempts to determine the prognostic
significance of DNA ploidy and SPF in patients with
operable T2-T4a (UICC, 1978) transitional cell carcinoma
(TCC) of the bladder, all of them scheduled for total cystec-
tomy. In addition, the relation of DNA ploidy and SPF to
immunohistochemically demonstrated p53 protein (Sidransky
et al., 1991, c-erbB-2 protein (Moriyama et al., 1991; Wright
et al., 1990; Coombs et al., 1991) and HCG (Iles & Chad,
1991) was studied.
Patients and methods
Patients
From 1980 throughout 1990, 186 patients were referred to
the Norwegian Radium Hospital (NRH) for pre-cystectomy
oncological treatment of T2-T4a TCC of the urinary bladder.
The present series deals with 118 of these patients for whom
paraffin blocks of the pre-treatment biopsies could be col-
lected for successful performance of DNA FCM.
The median age of the patients was 66 years (range: 39-80
years) (Table I). There were 90 males and 28 females. Sixty-
seven patients had newly diagnosed bladder cancer (interval
from initial diagnosis to start of pre-cystectomy radiotherapy
<4 months), whereas 51 patients had been treated for
superficial bladder cancer for several months or years before
muscle invasion was diagnosed. T categorisation was per-
formed by the referring urologist based on the UICC recom-
mendations (UICC, 1978).
Treatment
Eleven institutions referred their patients for pre-cystectomy
oncological treatment. Radiotherapy was delivered by a
linear accelerator (6 or 10 MeV) to parallelly opposed
anterior and posterior fields reaching from the lower edge of
the foramina obturatoria to the disc between the 5th lumbar
vertebra and the sacral bone, the lateral margins including
1 cm of the pelvic wall. The daily fraction was 4 Gy, given
from Monday to Friday (total dose: 20 Gy).
In 58 patients radiotherapy was preceded by 2 or 3 three-
weekly cycles of cisplatin-based chemotherapy. In the early
1980s this therapy was a part of a feasibility study conducted
at the NRH to introduce the idea of neo-adjuvant chemo-
therapy (23 patients). From 1986 35 patients were entered
into the 1st Nordic Cystectomy Trial (Rintala et al., 1992) or
had neo-adjuvant chemotherapy with cisplatin, Methotrexate
and Velbe (CMV) (Fossa et al., 1992). The doses of cisplatin
per cycle were 70 -00 mgm-2 combined either with doxo-
rubicin (30 mgm2) or Methotrexate (30 mgm-2) + Velbe
(4 mg m-2).
Total cystectomy was to be performed by the referring
urologist within 1 week after radiotherapy. In men the pros-
tate was to be removed together with the bladder and in
women the urethra, uterus and the anterior wall of the
vagina. Performance of pelvic lymphadenectomy was option-
al. In general, cystectomy was not performed if metastatic
pelvic lymph nodes were histologically demonstrated during
laparotomy by frozen sections. Pre-operatively detected
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tumour infiltration to the pelvic wall or intra-abdominal
metastases represented another contra-indication. In one
patient laparotomy was not performed as he developed
symptoms of Crohn's disease during the courses of chemo-
therapy and the urologist expected functional difficulties of
an ileal conduit. Thus 11 of the 118 patients had no cystec-
tomy.
Follow-up
During the first 5 years after cystectomy patients were fol-
lowed up with 3-6 months intervals at the local hospital
with the aim to diagnose pelvic or distant relapse. Thereafter
patients had yearly control examinations. For all patients the
median observation time up to March 1st 1992 was 32
months (1-147 months).
Light microscopy
The 118 pre-cystectomy biopsies were fixed in buffered 10%
formalin and embedded in paraffin. Fivejtm sections were
cut from the blocks and stained with haematoxylin and eosin
for light microscopical evaluation. The carcinomas were
graded according to UICC's recommendations (UICC, 1978)
and depth of invasion was recorded. In 95% of the biopsies
muscle invasion was histologically demonstrated before onco-
logical pre-cystectomy treatment started.
All pre-treatment biopsies were re-evaluated by one
pathologist (Aa.B.) for the purpose of the present investiga-
tion. The cystectomy specimens were evaluated by the
Department of Pathology at the local hospital, recording the
depth of infiltration (pT) and - if possible - the pathological
N-category (pN). The information on depth of tumour
infiltration in the cystectomy specimens was used to estimate
stage reduction (= no muscle infiltration demonstrated in the
cystectomy specimen; pT category < pT 1). Patients who
underwent laparatomy but not cystectomy were included in
the 'no stage reduction' group.
DNAflow cytometry
Blocks of formalin fixed and paraffin-embedded tumour tis-
sue from pre-treatment biopsies were selected. From each
block a 100tim section was cut and processed according to
Schiitte et al. (1985) with slight modifications (Jacobsen et
al., 1992). Briefly, the 100 tm sections were washed twice for
30 min in xylene, then washed in absolute alcohol and rehy-
drated with decreasing concentrations of alcohol. After cent-
rifugation at 350 g the specimens were incubated overnight
with trypsin 0.034% (Sigma T-8128) at 37°C in citrate buffer
solution. After filtration through a 60f.m nylon mesh, the
single nuclear suspensions were centrifuged at 350g for
5 min. Then the specimens were stained with propidium
iodide (Vindel0v et al., 1983).
DNA FCM in nuclear suspensions was performed in a
laboratory built flow cytometer based on a Nikon inverto-
scope and equipped with a mercury lamp of fluorescence
optics (Steen & Lindmo, 1979). The output signals > 580 nm
were sorted by a multichannel analyser (Nuclear Data Inc.,
Illinois), set up in groups of 256 channels and presented as
histograms.
Histograms with GO/GI peaks displaying a coefficient of
variation (CV) of > 10% were excluded from the final
analysis. As internal standards have been shown to be of no
value when interpreting DNA histograms from paraffin-
embedded material (Hedley et al., 1983), the first distin-
guishable peak was defined as the DNA diploid GO/G1 peak
with a DNA index (DI) of one. If more than one GO/GI
peak was present, DNA ploidy was calculated using the
DNA diploid GO/GI peak as a reference. A GO/GI peak in
the DNA tetraploid region was distinguished from the G2
peak of the diploid cell population by the presence of a G2
peak in the DNA octoploid region, or if it contained more
nuclei than the S-phase of the diploid peak. The DNA ploidy
regions were defined as DNA diploid (DNA index [DI]
1-1.1), DNA tetraploid (DI: 1.8-2.2) and DNA aneuploid,
the region between the DNA diploid and DNA tetraploid
range and above the tetraploid region (Hiddemann et al.,
1984). Tumours with only one DNA non-diploid stemline
were discriminated from those with two or more DNA non-
diploid stemlines. If a histogram revealed a DNA tetraploid
and a DNA aneuploid stemline, the tumour was charac-
terised as DNA aneuploid.
The fraction of counts in the S-phase region could be
calculated in 101 tumours using the MultiCycle program
(Phoenix Flow System, San Diego, USA) with automated
peak detection for up to 3 GI peaks and a subtraction
function for background including sliced nuclei. The median
SPF for DNA diploid and DNA non-diploid tumours was 6
and 21%, respectively. DNA diploid tumours with SPF
values >6% were grouped together with DNA non-diploid
tumours with the SPF values >21%. This high SPF group
was compared with low SPF group (i.e. DNA diploid and
DNA non-diploid tumours with SPF values below the
respective medians).
Immunohistochemistry
The pre-treatment biopsies were also paraffin-embedded used
for immunohistochemistry by applying the avidin-biotin
peroxidase complex (ABC) method (Hsu et al., 1981). After
removal of paraffin, the sections were treated for 30 min with
0.3% hydrogen peroxide in methanol to block endogenous
peroxidase, followed by 20 min incubation with non-reactive
serum diluted 1.75 in 0.001 M phosphate buffered saline
(pH 7.4) containing 5% bovine serum albumin (BSA) to
eliminate non-specific staining. The sections were then
incubated with the primary antibody (anti-p53 diluted 1:300
[Novocastra, UK] overnight at 4°C, anti-c-erbB-2 diluted
1:40 [NCI CB11 Novocastra, UK] and anti-HCG diluted
1:200 (Biotest) at 20°C for 30 min followed by 30 min
incubation of the biotin-labelled secondary antibody at
60 min incubation with ABC (10Lgml - avidin and
2.5 1tg 1' biotin-labelled peroxidase). The tissues were stained
for 5 min with 0.05% 3'3 diaminobenzidinetetrahydrochloride
freshly prepared in 0.05% tris buffer (pH 7.6) containing
0.01% hydrogen peroxide and counter-stained with haema-
toxylin, dehydrated and mounted.
Localisation of the immunostaining in relation to cellular
morphology was noted, and the fraction of immunoreactive
tumour cells was semiquantitatively graded from 0 to + + +
in each section.
Control studies included (1) relevant positive controls, (2)
the use of non-immune serum of IgG of the same fractions as
first layer and (3) incubation with primary antibody preab-
sorbed with relevant antigen. All controls gave satisfactory
results.
Statistics
Medians, ranges and chi-square statistics were calculated by
means of the PC-based Medlog program. Cancer-related sur-
vival was assessed by the Kaplan Meier method. Differences
between survival curves were evaluated by the Logrank test.
A P-value <0.05 was considered to be statistically signifi-
cant.
Results
Clinical outcome
The cancer-related 5-year survival for all patients was 60%
with no significant difference between the T categories (T2 vs
T3/T4a). Stage reduction was seen in 48 patients, 26 of
whom had completely tumour-free cystectomy specimens. In
patients who had received chemotherapy the 5-year survival
rate was 80% as compared to 50% in patients without
neo-adjuvant chemotherapy (P = 0.10).574 S.D. FOSSAetal.
Table I Patient characteristics
T category
T2
T3
T4a
Age (years)
Interval from initial diagnosis to cystectomy:
(months)
Grade (WHO)
1
2
3
Neoadjuvant chemotherapy
Yes
No
Cystectomy performed
Yes
No
Observation time
All patients
Surviving patients only
aMedian; bRange.
DNA ploidy
There were 16 DNA diploid tumours and 10'
diploid tumours, 30 of them being DNA tetr;
I). Thirty-one of the DNA non-diploid tumot
than 1 DNA stemline. DNA ploidy was not Cc
47
64
7
66a (39 80)b
4a (1-177)b
the pre-cystectomy T category, the occurrence of stage reduc-
tion of the pN category, independent whether DNA diploid
tumours were compared with DNA non-diploid TCC or the
discrimination was done between TCC with one or with two
or more DNA stemlines. Neither was there any correlation
between DNA ploidy and survival (Figure 1).
S-phasefraction
28 No correlation was found between SPF and the T- or pN
89 category (Table III). Stage reduction and WHO grade 3 were
more often found in the high SPF group than among
58 tumours with low SPF (P=0.006 and P=0.04). Patients
60 with high SPF tumours appeared to show a slightly better
5-year survival than those with low SPF tumours but this
107 was not statistically significant (P=0.19, Figure 2), unless
11 neo-adjuvant chemotherapy had been given (P<0.05, Figure
32 (1-147) 3). This latter finding is consistent with the observation that
42 (1-147) stage reduction was most often seen in high SPF tumours if
42(1-147) the patients had received neo-adjuvant chemotherapy (Table
IV). No difference of survival was observed between the SPF
groups if no chemotherapy was given (Figure 4).
2 DNA non- Immunohistochemistry
aploid (Table Forty-eight of 95 evaluable tumours (51%) stained for p53
urs had more protein (Table V). Com-parable figures for HCG and c-erbB-2
)-rrelated with were 12 and 9%, respectively. No correlation was found
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Figure 1 Cancer-related survival and DNA ploidy in 118 patients with T3/T2/T4a bladder cancer undergoing pre-operative
radiotherapy and total cystectomy ± neo-adjuvant chemotherapy. ( ) number of patients within the subgroup.
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Figure 2 Cancer-related survival and S-phasefraction (SPF) in patients with T2/T3/T4a bladder cancer undergoing pre-operative
radiotherapy and total cystectomy ± neo-adjuvant chemotherapy. ( ) Number of patients within the subgroup.
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Table II DNA ploidy and clinical/histopathological parameters
DNA non-diploid
DNA diploid DNA tetrapl. DNA aneupl. DNA non-dipl. Total
16a 30 72 102 118
T-category
T2 6 9 32 41 47
T3/T4a 10 21 40 61 71
Grade WHO
1/2 7 6 16 22 29
3 9 24 56 80 89
Stage reduction
Yes 5 12 31 43 48
(P <T1)
No 11 18 40 58 69
( >pT2)
Not evaluableb 1 1 1
pN category
pN0 8 8 26 34 42
,>pN1 2 7 15 22 24
Not evaluable 6 15 31 46 52
aNumber of patients in the group. bNo laparatomy done.
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Figure 3 Cancer-related survival and S-phasefraction (SPF) in patients with T2/T3/T4a bladder cancer undergoing pre-operative
radiotherapy and total cystectomy with neo-adjuvant chemotherapy. ( ) Number of patients within the subgroup.
No chemotherapy
HIGH SPF (23)
p: 0.83
. ---..-..--...LOW SPF (26)
6 12 24 36
Months from radiotherapy start
Figure 4 Cancer-related survival and S-phasefraction (SPF) in patients with T2/T3/T4a bladder cancer undergoing pre-operative
radiotherapy and total cystectomy without neo-adjuvant chemotherapy. ( ) Number of patients within the subgroup.
between the DNA ploidy and the assessed immunohisto-
logical parameters. On the other hand, significantly more p53
protein positive tumours were observed in the low SFP group
than the high SPF group (P= 0.02; Table VI). There was no
statistically significant difference between the survival of
patients with p53 protein positive tumours (54%) compared
with those with p53 protein negative TCC (68%, P =
0.40).
The clinical management (cystectomy ± neo-adjuvant onco-
logical treatment) and the overall outcome (60% 5-year
disease-related survival) of the 118 patients from the present
series are comparable to other published series presenting the
results of total cystectomy in patients with operable muscle-
invasive bladder cancer (Batata et al., 1981; Scanlon et al.,
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Table III S-phase fraction (SPF) and clinical/histopathological
parameters
Low SPF High SPF Total
(57)a (44) (101)
T-category
T2 24 17 41
T3/T4a 33 27 60
WHO Gradeb
2 15 4 19
3 42 40 82
Stage reductioncd
Yes 18 22 40
No 39 21 60
pN categoryd
pNO 21 18 39
>pNl 8 11 19
aNumber of patients within the group; bp<O.ool; cP<0.005;
dEvaluable patients only.
Table IV Chemotherapy, S-phase fraction (SPF) and stage
reduction
No chemotherapy Chemotherapy +
Low SPF High SPF Low SPF High SPF
(31)a (22) (26) (21)b
Stage reduction
Yes 7 7 11 15
No 24 15 15 6
aNumber of evaluable patients in the group. bp<0.08 comparing
both groups.
1983; Pagano et al., 1988; Splinter et al., 1992; Rintala et al.,
1992; Parson & Million, 1988). Our observations from the
118 patients, can thus be regarded generally applicable for
patients with muscle-invasive bladder cancer scheduled for
total cystectomy. A detailed analysis of the clinical para-
meters for all 186 patients will be an issue of a future
report.
DNA ploidy determination in paraffin-embedded tumour
material yields reliable and reproducible results in our hands.
However, some inter-laboratory variation occurs in about
10% of the cases and has to be taken into account when
comparing results from different groups (Coon et al., 1988;
Fossa et al., 1992). We found that about 15% of our patients
had DNA diploid tumours. This percentage is lower than
reported in other series using paraffin-embedded material,
including a previous report from our own group (Hug et al.,
1992; Malmstr0m et al., 1989; Jacobsen et al., 1987; Badala-
ment et al., 1990). The DNA diploidy rate of 15% is com-
parable to the figure of 10% reported by Wijkstrom and
Tribukait (1990) when using fresh tumour samples.
Table VI S-phase fraction (SPF), p53 protein, HCG and c-erbB-2
protein
Low SPF High SPF Total
p53 protein (65)a
Negative 10 21 31
Positive 22 12 34
+ 9 3 12
++ 6 2 8
+++ 7 7 14
HCG (61)a
Negative 26 31 57
Positive 2 2 4
c-erbB-2 protein (60)a
Negative 26 29 55
Positive 2 4 6
aNumber of evaluable tumours.
DNA diploidy is not identical to the normal chromosomal
number. Small quantitative DNA deviations may remain
below the detection limit by FCM. Furthermore, DNA dip-
loid and DNA near-diploid bladder tumours, as determined
by FCM, may display cytogenetic deviations (Wijkstr6m et
al., 1984; Coon et al., 1986). In addition, from image
cytometric studies it is obvious that some of the DNA dip-
loid tumours contain small amounts of DNA non-diploid
tumour cells, not detectable by FCM (Dawson et al.,
1990).
Our SPF values are within the ranges published by Lip-
ponen et al. (1991) using similar techniques, and display
significant differences between SPF values in DNA diploid
and DNA non-diploid tumours. Evaluation of SPF by FCM
yields, however, much less reliable and less reproducible
observations, than DNA ploidy (Haag et al., 1987) especially
if paraffin-embedded tissue is used. The reasons for this
variability may be randomly distributed (preparation techni-
que, quality of the paraffin-embedded material) and are not
easily compensated for. In addition, nuclear suspensions
from sections contain sliced nuclei which contribute a system-
atic source of error when the SPF is determined. Some, but
not all of these systematic errors can be accounted for by the
computer program which calculates the different phases of
the cell cycle. Using specially designed calculation programs
for SPF acceptable correlations have been obtained between
SPFs in fresh and paraffin-embedded tissue (Weaver et al.,
1990; Jacobsen et al., 1992). In spite of all uncertainties in
determination of SFP in cell suspensions from paraffin-
embedded material SPF represents a clinical significant
parameter in studies in human tumours (Merkel & McGuire,
1990). SPF determined by DNA FCM was therefore included
in the present analysis.
The present homogeneous series of patients with muscle-
invasive TCC confirms our and other authors' experience
(Wijkstr6m et al., 1992; Jenkins et al., 1990) on the very
limited prognostic role of DNA ploidy in muscle-invasive
bladder cancer. In a previous series DNA tetraploidy proved
Table V DNA ploidy, p53 protein, HCG and c-erbB-2 protein
DNA DNA non-diploid
diploid DNA tetraploid DNA aneuploid DNA non-diploid Total
p53 protein (95)a
Negative 8 12 29 41 49
Positive (all) 4 12 30 42 46
+ 2 6 13 19 21
++ 1 3 3 6 7
+++ 1 3 14 17 18
HCG (95)a
Negative 12 19 53 72 84
Positive 0 6 5 11 11
c-erbB-2 protein (94)a
Negative 11 23 52 75 86
Positive 1 2 5 7 8
aNumber of evaluable tumours.DNA PLOIDY AND S-PHASE FRACTION IN BLADDER CANCER 577
to be an independent prognostic parameter in patients receiv-
ing definitive radiotherapy (Jacobsen et al., 1989). This find-
ing was not supported by the present series consisting of
operable bladder cancer. Our present results are in agreement
with our previous findings (Jacobsen et al., 1991) and a
recent report by Hug et al. (1992) who confirmed that
muscle-invasive bladder cancer with DNA diploid stemlines
did not display a particularly favourable prognosis as might
be expected.
Histological grade has in general been shown to correlate
with proliferative activity in TCC, consistent with the present
observations (Lipponen et al., 1991; Tribukait et al., 1982).
Based on results from DNA flow cytometry in paraffin-
embedded specimens Lipponen et al. (1991) and Shaaban et
al. (1990) have suggested that a high SPF was correlated with
the presence of regional lymph node metastases, a finding
which is not supported by our results. In a preliminary report
we have found a better prognosis for heterogeneously treated
patients with advanced bladder cancer and high SPF when
chemotherapy was given (Jacobsen et al., 1992). This obser-
vation is confirmed in the present larger and homogeneous
series where chemotherapeutically treated patients with high
SPF tumours more often experienced stage reduction and
had a better prognosis than those with low SPF. The reason
may be that high SPF tumours due to their higher prolifera-
tion rate respond better to the combined neo-adjuvant ono-
logic treatment (chemotherapy and radiotherapy) than do
low SPF tumours. This correlation between SPF and stage
reduction/prognosis suggests that patients with high SPF
tumours should be offered pre-cystectomy treatment whereas
such therapy is less indicated in patients with low SPF
tumours.
The p53 suppressor gene participates in the cell cycle
regulation (Levine et al., 1991). The mutant p53 is assumed
to inhibit normal p53 but there is also evidence for a direct
oncogenic effect. Most studies suggest that p53 gene muta-
tions arise relatively late in malignant progression. Mutations
of the p53 gene have been reported in many human tumours
(Porter et al., 1992). Compared with other series reporting on
frequency of the p53 gene mutations or its protein expression
in bladder cancer (Sidransky et al., 1991; Porter et al., 1992)
a relative high percentage (51%) of p53 protein positive
bladder tumours was found in the present study. This might
be due to the fact that all patients had muscle-invasive
bladder cancer and more than 60% had deeply infiltrating
TCC () T3). Fujimoto et al. (1992) have, for example,
shown an increase of p53 gene mutations as bladder tumours
become muscle-invasive.
We observed a high percentage of p53 positive tumours in
the low SPF group, a relation which was maintained even
when only p53 protein positive tumours graded as + + or
+ + + were considered. This observation is intriguing on the
background of a recent report by M0rkve and Lhrum (1991),
who found a positive correlation between p53 reactivity and
SPF when single cells from lung carcinoma were evaluated
simultaneously by FCM. This discrepancy may be due to
intra-tumoural heterogeneity and/or methodological
differences between M0rkve and Lxrum's observations and the
present ones. Further experience in large homogeneous
clinical series will be necessary to evaluate the clinical role of
p53 in muscle-invasive bladder cancer.
Only about 10% of all bladder tumours in the present
series were HCG and c-erbB-2 protein positive. These percen-
tages are lower than reported previously by other groups
(Wright et al., 1990; Moriyama et al., 1991; Coombs et al.,
1991; Jenkins et al., 1990; Iles & Chard, 1991), but are
consistent with another series from our group (Jacobsen et
al., 1990). We have not been able to confirm a correlation
between DNA non-diploidy and c-erbB-2 protein immuno-
reactivity as indicated in our previous report on a more
heterogeneous series (Berner et al., 1992).
From the present series we summarise that DNA ploidy
does not represent a prognostic parameter in patients who
clinically are deemed to have operable muscle invasive TCC
of the urinary bladder. However, patients with high SPF
tumours seem to benefit from combined neo-adjuvant cyto-
static and radiotherapeutic treatment more than those with
low SPF tumours. About half of the bladder tumours were
p53 protein positive, though the clinical relevance of this
finding remains undetermined.
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